Stock Library / MEDP

MEDP Healthcare Latest YouTube: Q2 2026 Published 2026-07-23

Medpace Holdings, Inc.

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

Medpace Stock (MEDP): Growth Just Roared Back and It Popped 17% — Are You Too Late?

Published 2026-07-23

Open YouTube Spotify Show Open Podbean Apple Podcasts

Library coverage

Episodes tracked

3

Episodes linked

3

Latest video

Q2 2026

2026-07-23

Podcast available

Yes

Current price

$620.75

+9.75 (+1.60%)

Trailing / Forward P/E

36.49x

Forward: 32.15x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

17.2%

Earnings: 37.1%

Margins

20.8% op

Gross: 72.3% · Net: 17.7%

Balance sheet

0.73x current

Debt / Equity: 33.2

52-week range / Beta

$373.00 - $677.90

Beta: 1.15

Analyst target

$581.83

Upside: -6.3%

Cash / shareholder return

2.95% FCF yield

Dividend yield: —

Company context

Industry: Diagnostics & Research

Country: United States

Employees: —

Price to book: 39.93x

Return on equity: 162.2%

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Price chart

Market context for MEDP

Competitive view

MEDP vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Medpace Holdings, Inc. latest YouTube video thumbnail

Medpace Holdings, Inc.

MEDP

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Intuitive Surgical latest YouTube video thumbnail

Intuitive Surgical

ISRG

YouTube Spotify Podbean Apple

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Johnson & Johnson latest YouTube video thumbnail

Johnson & Johnson

JNJ

YouTube Podbean Apple

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

MEDP

$17.33B

Medpace Holdings, Inc.

ISRG

$135.72B

Intuitive Surgical

JNJ

$651.25B

Johnson & Johnson

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

MEDP

36.5x

Medpace Holdings, Inc.

ISRG

43.5x

Intuitive Surgical

JNJ

31.4x

Johnson & Johnson

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

MEDP

32.1x

Medpace Holdings, Inc.

ISRG

31.4x

Intuitive Surgical

JNJ

22.0x

Johnson & Johnson

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

MEDP

17.2%

Medpace Holdings, Inc.

ISRG

18.5%

Intuitive Surgical

JNJ

6.6%

Johnson & Johnson

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

MEDP

37.1%

Medpace Holdings, Inc.

ISRG

26.5%

Intuitive Surgical

JNJ

-0.9%

Johnson & Johnson

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

MEDP

20.8%

Medpace Holdings, Inc.

ISRG

33.6%

Intuitive Surgical

JNJ

29.2%

Johnson & Johnson

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

MEDP

72.3%

Medpace Holdings, Inc.

ISRG

66.7%

Intuitive Surgical

JNJ

68.1%

Johnson & Johnson

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

MEDP

17.7%

Medpace Holdings, Inc.

ISRG

28.4%

Intuitive Surgical

JNJ

21.5%

Johnson & Johnson

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

MEDP

162.2%

Medpace Holdings, Inc.

ISRG

17.4%

Intuitive Surgical

JNJ

25.7%

Johnson & Johnson

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

MEDP

3.0%

Medpace Holdings, Inc.

ISRG

1.9%

Intuitive Surgical

JNJ

2.6%

Johnson & Johnson

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

MEDP

33.22x

Medpace Holdings, Inc.

ISRG

—

Intuitive Surgical

JNJ

57.71x

Johnson & Johnson

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

MEDP

0.73x

Medpace Holdings, Inc.

ISRG

4.96x

Intuitive Surgical

JNJ

1.09x

Johnson & Johnson

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

MEDP

1.15

Medpace Holdings, Inc.

ISRG

1.46

Intuitive Surgical

JNJ

0.23

Johnson & Johnson

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

MEDP

—

Medpace Holdings, Inc.

ISRG

—

Intuitive Surgical

JNJ

2.0%

Johnson & Johnson

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

MEDP

-6.3%

Medpace Holdings, Inc.

ISRG

26.2%

Intuitive Surgical

JNJ

0.8%

Johnson & Johnson

Related research

Non-quarter videos featuring MEDP

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-07-22

Medpace stock popped 17% — too late to buy? #MEDP #stocks #investing

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for MEDP

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-07-23

Published youtube podcast complete

Medpace Stock (MEDP): Growth Just Roared Back and It Popped 17% — Are You Too Late?

Quarterly earnings-analysis entry for Medpace Holdings, Inc.. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music

Q1 2026

Episode live

2026-04-23

Published youtube complete

Medpace (MEDP) Earnings: Revenue Up 27%, Book-to-Bill Slips | Q12026

Quarterly earnings-analysis entry for Medpace Holdings, Inc.. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podbean Show Apple Podcasts Amazon Show iHeart Show YouTube Music

Deep Dive

Episode live

2026-04-23

Published podcast complete

Charged Alpha | Medpace Holdings (MEDP) | S&P 500 Deep Dive — Ep. 161

Quarterly earnings-analysis entry for Medpace Holdings, Inc.. Use the links on the right to open the video or podcast episode.

Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music